Durham-based Novan has closed its first day of trading on the Nasdaq up 65 percent at $18.10. The drugmaker – which manufactures a treatment for acne without the use of antibiotics – priced its initial public offering at $11 per share.
The offering is expected to close Monday.
Earlier this month, Novan (Nasdaq: NOVN) announced that it expected to raise roughly $39 million through its IPO, down from an original forecast of as much as $60 million. While Novan had initially planned to sell 3.75…
Durham-based Novan has closed its first day of trading on the Nasdaq up 65 percent at $18.10. The drugmaker – which manufactures a treatment for acne without the use of antibiotics – priced its initial public offering at $11 per share.
The offering is expected to close Monday.
Earlier this month, Novan (Nasdaq: NOVN) announced that it expected to raise roughly $39 million through its IPO, down from an original forecast of as much as $60 million. While Novan had initially planned to sell 3.75…